PTC Therapeutics
PTC Therapeutics
PTC Therapeutics (pronounced: P-T-C Therapeutics) is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically-differentiated medicines. The company's mission is to provide patients with new treatments for rare disorders.
Etymology
The name "PTC" stands for "Post Transcriptional Control", referring to the company's focus on the development of drugs that target processes occurring after the transcription of DNA into RNA.
History
PTC Therapeutics was founded in 1998 by Dr. Stuart Peltz and Dr. Allan Jacobson, with the aim of leveraging advances in the understanding of post-transcriptional control processes to develop new therapeutics. The company is headquartered in South Plainfield, New Jersey, United States.
Products and Research
PTC Therapeutics has a broad pipeline of drugs in various stages of development, targeting multiple therapeutic areas including rare diseases, oncology, and infectious diseases. The company's first approved product is Translarna™ (ataluren), a treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD).
Related Terms
- Biopharmaceutical
- Rare diseases
- Oncology
- Infectious diseases
- Duchenne muscular dystrophy
- Transcription (genetics)
- RNA
External links
- Medical encyclopedia article on PTC Therapeutics
- Wikipedia's article - PTC Therapeutics
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski